Anti-Adalimumab Antibodies in Patients with Noninfectious Uveitis Who Use Adalimumab Weekly or Every Other Week
ADA is mostly associated with favorable clinical response in treating NIU. In insufficient clinical response, the dose escalation method may increase treatment success. AAA formation may not be the only factor in the ineffectiveness of treatment.
Authors
- Asuman Bırıncı (ORCID: https://orcid.org/0000-0002-8653-4710)
- Hilal Eser-Öztürk (ORCID: https://orcid.org/0000-0002-0050-7894)
- Leman Ismayilova
- Yüksel Süllü (ORCID: https://orcid.org/0000-0001-9818-671X)
Institutions
- Ondokuz Mayıs University (TR)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1080/09273948.2025.2487164
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00